Valneva Provides Update on IXCHIQ® in the United Kingdom

The UK's MHRA revoked the marketing authorization for Valneva's chikungunya vaccine IXCHIQ following a further benefit-risk assessment by the Commission on Human Medicines; the decision was based on prior safety data, with no newly identified safety signal. Financial impact is minimal: Valneva had already stopped distributing IXCHIQ in the UK due to low traveler sales, expects no recall expense, and sees only minimal revenue impact going forward. Licenses in the EU, Canada, Brazil and other territories remain intact.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.